Hyperprolactinemia during application of second-generation antipsychotics: the principles of prevention, diagnosis and correction
Abstract
The article presents compelling evidence of the need to draw attention of physicians to the problem of neyroleptical hyperprolactinemia. The article provides information about different prolactogen activity of antipsychotics with the release of the safest drugs - aripiprazole and ziprasidone. Substantiates the necessity of correction prolactin levels during antipsychotic therapy. Presented the algorithms for the prevention and monitoring of neuroleptic hyperprolactinemia, as well as the basic principles of its correction, including with the use of a dopamine agonist Dostinex.
About the Authors
L. N. Gorobets
Federal State Institution «Scientific Center of Psychiatry and Narcology named by V.P. Serbsky» of Health Ministry of Russia - a branch of the Moscow Research Institute of Psychiatry
Russian Federation
Russian Federation
G. E. Mazo
St. Petersburg V.M. Bekhterev Research Psychoneurological Institute
Russian Federation
Russian Federation
References
1. Горобец Л.Н., Мазо Г.Э. Нейроэндокринные дисфункции при использовании психофармакотерапии: клиника, диагностика, факторы риска и коррекция // Журнал неврологии и психиа трии имени С.С. Корсакова. - 2014. - Том 114, №10. - С. 122-130.
2. Мазо Г.Э., Никифорова Ю.С., Щедрина Л.В. Влияние депрессии при шизофрении на уровень BDNF. Журнал Психиатрия и Психофармакотерапия» им. П.Б. Ганнушкина. - 2015. - том 17. - №1. - С. 12-17.
3. Ajmal A., Joffe H., Nachtigall L.B. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. - 2014. - Vol. 55. - P. 29-36.
4. Alpay M.A., Tutuncu R., Oner I. et al. Relationship between plasma levels of prolactin and the severity of negative symptoms in patients with schizophrenia. - Bull.Clin. Psychopharmacol. - 2015. - Vol. 25. - P. 27-37.
5. Azorin J.-M., Strub N., Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia // Int. Clin. Psychopharmacol.-2006.- Vol. 21.-P. 49-56.
6. Basson R., Rees P., Wang R.X. et al. Sexual function in chronic illness. - J Sex Med. - 2010. - 71. - P. 374-388.
7. Bushe C., Shaw M., Peveler R. A review of the association between antipsychotic use and hyperprolactinaemia. - J Psychopharmacol. - 2008. - Vol. 22. - P. 46-55.
8. Bushe C.J., Bradley A., Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry. - Ann Clin Biochem. - 2010. - Vol. 47. - P. 292-300.
9. Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis // J Psychopharmacol. - 2008. - Vol. 22. - P. 90.
10. Cookson J, Hodgson R, Hiram JW. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis. -J Psychopharmacol. - 2012. - Vol. 26. - P. 42-51.
11. Crawford A.M., Beasley C.M. Jr, Tollefson G.D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. - Schizophr Res. - 1997. - Vol. 26. - P. 41-54.
12. Fagiolini A., Montejo A.L., Thomas P. et al. Physical health considerations in psychiatry: views on recognition, monitoring and management. - Eur Neuropsychopharmacol. - 2008. - Vol.18. - P. 10.
13. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management // Drugs. - 2004. - Vol. 64, N. 20. - P. 2291-2314.
14. Hough D., Lindenmayer J.P., Gopal S. et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia // Biol. Psychiatry. - 2009. - Vol. 33, №6. - P. 1022-1031.
15. Grootens K. P., van Veelen N. M. J., Peuskens J. et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. - Schizophr. Bull. - 2011. - Vol. 37. - P. 352-361.
16. Inder W.J., Castle D. Antipsychotic-induced hyperprolactinaemia. -Aust N Z J Psychiatry. - 2011. - Vol.45. - P.830-837.
17. Juruena M.F., Pondé de Sena E., Reis de Oliveira I. Safety and tolerability of antipsychotics: Focus on amisulpride. - Drug Healthc Patient Saf. - 2010. - Vol. 2. - P. 205-211.
18. Kanea J.M., Khannab S., Rajadhyaksha S. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. - Int. Clin. Psychopharmacol. - 2006. - Vol. 21. - P. 21-28.
19. Kelly D.L., Wehring H.J., Earl A.K. et al. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist Aripiprazole, for the Management of Symptomatic Elevated prolactin). - BMC Psychiatry. - 2013. - Vol. 13. - P. 214.
20. Laita P., Cifuentes A., Doll A. et al. Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. - J Child Adolesc Psychopharmacol. - 2007. - Vol. 17. - P. 487-502.
21. Lally J., MacCabe J.H. Antipsychotic medication in schizophrenia: a review. - Br. Med. Bull. - 2015. - Vol. 114. - P. 169-179.
22. Leucht S., Cipriani A., Spineli L. et. al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. - Lancet. - 2013. - Vol.382. - P. 951-962.
23. Loonen A.J., Ivanova S.A. Role of 5-HT2C receptors in dyskinesia. - Int J Pharm Pharm Sci. - 2016. - Vol. 8. - P. 5-10.
24. Madhusoodanan S., Parida S., Jimenez C. Hyperprolactinemia associated with psychotropics - a review // Hum. Psychopharmacol. Clin. Exp. - 2010. - Vol. 25. - P. 281-297.
25. Montalvo I., Gutierrez-Zotes A., Creus M. Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis. Plos One. February. - 2014. - Vol. 9, Issue 2. - P. 1-9.
26. Montejo A.L. Prolactin awareness: an essential consideration for physical health in schizophrenia. - Eur. Neuropsychopharmacol. - 2008. - Vol.18, Suppl. 2, - P. 101-130.
27. Montejo A.L., Majadas S., Rico-Villademoros F. et al., for the Spanish Working Group for the Study of Psychotropic-Related Sexual. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. - J Sex Med. - 2010. - Vol. 7-P. 2013.
28. Nasrallah N., Gopal. S., Gassmann-Mayer C. et al. A controlled, evidence-based trial of palipepradone palminate, a lon-acting injectable antipsychotic, in schizophrenia // Neuropsychopharmacol. - 2010. - Vol. 10. - P. 2072-2082.
29. Paparrigopoulos T., Liappas J., Tzavellas E. et al. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. - Prog Neuropsychopharmacol Biol Psychiatry. - 2007. - Vol. 31. - P. 92-96.
30. Park Y.W., Kim Y., Lee J.H. Antipsychotic-induced sexual dysfunction and its management. - World J. Mens. Health. - 2012. - Vol.30. - P. 153-159.
31. Pérez-Iglesias R., Mata I. et al. Long-term effect of haloperi- dol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis. - J Clin Psychopharmacol. - 2012. - Vol. 32. - P. 804-808.
32. Peuskens J., Pani L., Detraux J. et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. - CNS Drugs. - 2014. - Vol. 28. - P. 421-453.
33. Riecher-Rössler A., Rybakowski J.K., Pflueger M.O. et al. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol. Med. EUFEST Study Group. - 2013. - Vol. 43. - P. 2571-2582.
34. Serretti A., Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. - Int. Clin. Psychopharmacol. - 2011. - Vol. 26. No 3. - P. 130-140.
35. Volavka J., Czobor P., Cooper T.B. et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. - J Clin Psychiatry. - 2004. - Vol. 65. - P. 57-61.
Review
For citations:
Gorobets L.N., Mazo G.E. Hyperprolactinemia during application of second-generation antipsychotics: the principles of prevention, diagnosis and correction. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2017;(1):63-69. (In Russ.)
Views:
636
Email this article 